News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
616,605 Results
Type
Article (47446)
Company Profile (239)
Press Release (568920)
Section
Business (177261)
Career Advice (2578)
Deals (32651)
Drug Delivery (117)
Drug Development (78906)
Employer Resources (162)
FDA (16247)
Job Trends (13628)
News (313804)
Policy (32481)
Tag
Academia (2414)
Alliances (44732)
Alzheimer's disease (1339)
Approvals (16185)
Artificial intelligence (154)
Bankruptcy (320)
Best Places to Work (10156)
Biotechnology (125)
Breast cancer (188)
Cancer (1396)
Cardiovascular disease (113)
Career advice (2146)
CAR-T (104)
Cell therapy (299)
Clinical research (63176)
Collaboration (471)
Compensation (275)
COVID-19 (2625)
C-suite (109)
Data (1349)
Diabetes (185)
Diagnostics (5482)
Drug pricing (106)
Earnings (68881)
Employer resources (147)
Events (93082)
Executive appointments (388)
FDA (16952)
Funding (395)
Gene therapy (213)
GLP-1 (697)
Government (3966)
Healthcare (15951)
Infectious disease (2722)
Inflammatory bowel disease (115)
Interviews (471)
IPO (15231)
Job creations (3865)
Job search strategy (1805)
Layoffs (470)
Legal (7847)
Lung cancer (211)
Manufacturing (222)
Medical device (11460)
Medtech (11464)
Mergers & acquisitions (17609)
Metabolic disorders (526)
Neuroscience (1688)
NextGen Class of 2024 (5515)
Non-profit (3428)
Northern California (1654)
Obesity (306)
Opinion (235)
Patents (126)
People (51799)
Phase I (19433)
Phase II (27436)
Phase III (21408)
Pipeline (525)
Postmarket research (2614)
Preclinical (7909)
Radiopharmaceuticals (233)
Rare diseases (278)
Real estate (5403)
Regulatory (22221)
Research institute (2226)
Resumes & cover letters (426)
Southern California (1393)
Startups (3332)
United States (14509)
Vaccines (644)
Weight loss (241)
Date
Last 7 days (173)
Last 30 days (1599)
Last 365 days (33240)
2025 (98)
2024 (33936)
2023 (37974)
2022 (48616)
2021 (52390)
2020 (49754)
2019 (40621)
2018 (30992)
2017 (31303)
2016 (30095)
2015 (33761)
2014 (27432)
2013 (23064)
2012 (24740)
2011 (25337)
2010 (23273)
Location
Africa (782)
Arizona (158)
Asia (38546)
Australia (6194)
California (3655)
Canada (1299)
China (301)
Colorado (169)
Connecticut (192)
Europe (86801)
Florida (526)
Georgia (119)
Illinois (350)
Indiana (197)
Maryland (625)
Massachusetts (2904)
Michigan (144)
Minnesota (262)
New Jersey (1087)
New York (1024)
North Carolina (741)
Northern California (1654)
Ohio (125)
Pennsylvania (865)
South America (1160)
Southern California (1393)
Texas (525)
Washington State (385)
616,605 Results for "bayer pharma s a".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Clinical research
Bayer’s Kidney Disease Drug Kerendia Reduces Cardiovascular Risk by 16%
Bayer’s Kerendia, at the center of a $3 billion sales forecast, reduced the risk of cardiovascular death and heart failure in a Phase III trial.
September 3, 2024
·
2 min read
·
Annalee Armstrong
Layoffs
Bayer, J&J and Pfizer to Lay Off Nearly 500 Combined Employees
Big Pharma companies Bayer and Johnson & Johnson are downsizing their New Jersey workforces while Pfizer cuts jobs in Ireland. Many of the layoffs are effective by the end of the year.
October 2, 2024
·
3 min read
·
Angela Gabriel
Earnings
Bayer Touts ‘Modest’ Q2 Performance Amid Sweeping Reorganization
Bayer’s surprising growth in the second quarter was driven in large part by two pharma products: the prostate cancer drug Nubeqa and the chronic kidney disease treatment Kerendia.
August 6, 2024
·
2 min read
·
Tristan Manalac
Postmarket research
Regeneron, Bayer Build Retinal Vein Occlusion Case for Eylea as Biosimilar Pressure Mounts
The Phase III win could help Regeneron and Bayer expand into retinal vein occlusion, a move that the partners need to help shore up sales of their Eylea franchise amid biosimilar encroachment.
December 17, 2024
·
2 min read
·
Tristan Manalac
Editorial
Pharma’s Q3 Was a Rollercoaster Ride. Let’s Do It Again Next Quarter
Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.
November 15, 2024
·
3 min read
·
Annalee Armstrong
Business
Bayer’s 1,500 Layoffs Are Latest Salvo in CEO Bill Anderson’s Company Overhaul
Since taking the helm in 2023, Anderson has embarked on a radical departure from the traditional structure of large pharma companies. Will getting rid of management layers fix Bayer?
May 17, 2024
·
3 min read
·
Greg Slabodkin
Startups
Roivant Creates New ‘Vant’ to License Bayer’s Pulmonary Hypertension Drug
Under an in-license agreement worth up to $294 million, Roivant Sciences gains exclusive worldwide rights from Bayer to develop and commercialize mosliciguat, a potential first-in-class inhaled soluble guanylate cyclase activator.
September 10, 2024
·
2 min read
·
Tristan Manalac
Layoffs
Bayer to Lay Off 150 in Basel, Switzerland
The Switzerland layoffs are the latest in Bayer’s 2024 workforce reductions, which already include 1,500 people and nearly half of the executive leadership team.
August 26, 2024
·
1 min read
·
Angela Gabriel
Earnings
Bayer Earnings ‘Not Pretty,’ CEO Bill Anderson Admits As He Urges Calm
Bayer reported a decline of 37% in earnings per share on Tuesday, which sent its stock down 12%. CEO Bill Anderson urged investors to be patient as the company executes on a performance-boosting strategy outlined in March.
November 12, 2024
·
2 min read
·
Annalee Armstrong
Biotech Bay
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
BridgeBio Pharma, Inc. and Bayer announced a partnership wherein BridgeBio grants Bayer an exclusive license to commercialize acoramidis for ATTR-CM in Europe.
March 4, 2024
·
7 min read
1 of 61,661
Next
